NIH will expand and strengthen commitments to respectfully engage American Indian and Alaska Native (AI/AN) people and support their inclusion in the All of Us Research Program.

Scientists have genetically engineered immune cells, called myeloid cells, to precisely deliver an anticancer signal to organs where cancer may spread.

NEI scientists have noninvasively visualized the light-sensing cells in the back of the eye, known as photoreceptors, in greater detail than ever before. The researchers improved imaging resolution by 33 percent by eliminating extraneous light.

Two years after establishing a human cerebral organoid system to study Creutzfeldt-Jakob disease (CJD), NIH researchers have further developed the model to screen drugs for potential CJD treatment.

A new finding about the mosquito protein AEG12 could lead to therapeutics against life-threatening viruses that afflict millions of people around the world.

NIH halted a clinical trial evaluating the safety and efficacy of Covid-19 convalescent plasma in treating emergency department patients who developed mild to moderate Covid symptoms.

An analysis of law enforcement seizures of illegal drugs in five key U.S. regions revealed a rise in methamphetamine and marijuana (cannabis) confiscations during the Covid-19 pandemic. Seizures of the two drugs were higher at their peak in August 2020 than at any time in the prior year.

A promising strategy to tame troublesome drug-resistant bacteria is bacteriophage, or phage therapy, which uses viruses instead of antibiotics. NIH scientists have used two different bacteriophage viruses individually and then together to successfully treat research mice infected with multidrug-resistant Klebsiella pneumoniae sequence type 258 (ST258).

In an NIH-led study, scientists found that five genes may play a critical role in determining whether a person will develop Lewy body dementia (LBD), a devastating disorder that riddles the brain with clumps of abnormal protein deposits called Lewy bodies.

Enrollment has begun to test additional investigational drugs in the Accelerating Covid-19 Therapeutic Interventions and Vaccines (ACTIV) program. ACTIV, sponsored by NIAID, is a public-private partnership that creates a coordinated research strategy to prioritize and speed development of promising Covid-19 treatments and vaccines.